Work

A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e14560

Authors: Ching-Liang Ho, Tsu-Yi Chao, Chia lun Chang, Hsuan-Yu Lin, Futang Yang, Qingyu Wang, Jun Zhu

Institutions: Tri-Service General Hospital, National Defense Medical Center, Ministry of Health and Welfare, Taipei Medical University-Shuang Ho Hospital, Taipei Medical University, Wan Fang Hospital, Changhua Christian Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286299173

Cites:

Cited by:

Related to: 10